Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–19 of 19 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT06948786
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT06442475
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, +16 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT04883437
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +18 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
Not Yet Recruiting
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
NCT07731789
- Conditions
- Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, +11 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT05169658
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT03410901
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +27 more
- Locations
-
- Stanford University, School of Medicine Palo Alto, California, United States
NCT02927964
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +17 more
- Locations
-
- Stanford University, School of Medicine Palo Alto, California, United States
NCT02532257
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
NCT01000753
- Conditions
- Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma, Childhood Immunoblastic Lymphoma, +35 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
NCT03010358
- Conditions
- Anemia, B-Cell Prolymphocytic Leukemia, Chronic Disease, +36 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
NCT01239875
- Conditions
- Adult Diffuse Mixed Cell Lymphoma, Adult Diffuse Small Cleaved Cell Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, +37 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Completed
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
NCT02652715
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, +76 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT01484015
- Conditions
- Adnexal Diseases, Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, +121 more
- Locations
-
- Wake Forest University Health Sciences Winston-Salem, North Carolina, United States
Active, Not Recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
- Locations
-
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
- Alaska Women's Cancer Care Anchorage, Alaska, United States
- Anchorage Oncology Centre Anchorage, Alaska, United States
Active, Not Recruiting
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04257578
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 1 Follicular Lymphoma, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
NCT04450173
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, +13 more
- Locations
-
- University of California, San Francisco (UCSF) Fresno Fresno, California, United States
- University of California, Los Angeles Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- University of California, San Diego San Diego, California, United States
Active, Not Recruiting
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026
- Conditions
- Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, +26 more
- Locations
-
- Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT02992522
- Conditions
- B-Cell, B-Cell Lymphoma, Unspecified, Burkitt Lymphoma, +30 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States